Appeals Court Nixes Savient Injunction Bid
On December 28, the U.S. Court of Appeals for the Federal Circuit denied Savient’s bid for a preliminary injunction, giving Sandoz Inc. and Upsher-Smith Laboratories Inc. the green light to launch generic oxandrolone products. Oxandralone is Oxandrin’s active ingredient.
Savient sued Sandoz and Upsher-Smith earlier this month in New Jersey for patent infringement, citing the defendants’ attempts to market generic...
To view the full article, register now.